Esperion Therapeutics (ESPR) Net Equity Issued and Repurchased (2013 - 2024)

Esperion Therapeutics' Net Equity Issued and Repurchased history runs 7 years deep, the most recent figure standing at -$90.2 million for Q4 2024.

• Quarterly Net Equity Issued and Repurchased fell 2126.96% year-over-year to -$90.2 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$90.2 million (down 194.78% YoY) and the FY2024 annual result came in at $513000.0, down 88.47% from the prior year.
• Net Equity Issued and Repurchased was -$90.2 million for Q4 2024 at Esperion Therapeutics, down from $90.7 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $90.7 million in Q1 2024 and bottomed at -$90.2 million in Q4 2024.
• A 4-year average of $13.2 million and a median of $12.8 million in 2021 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased jumped 1008.75% — and 2024, when it plunged 2126.96%.
• Esperion Therapeutics' Net Equity Issued and Repurchased stood at $5.3 million in 2021, then jumped by 312.92% to $22.0 million in 2022, then sank by 79.77% to $4.4 million in 2023, then plunged by 2126.96% to -$90.2 million in 2024.
• Business Quant data shows ESPR's Net Equity Issued and Repurchased at -$90.2 million in Q4 2024, $90.7 million in Q1 2024, and $4.4 million in Q4 2023.